GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for the treatment of rare diseases, particularly oncology. Its stock price is highly volatile and driven by news about the progress of its candidates' clinical trials.
Share prices of companies in the market segment - Pharmacy
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs to treat rare oncological and neurological diseases. We've classified it under the Pharmaceuticals category. The chart below shows how investors value biotech companies focused on orphan diseases.
Broad Market Index - GURU.Markets
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare oncological and neurological diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BDRX - Daily change in the company's share price Biodexa Pharmaceuticals
Biodexa Pharmaceuticals' daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about its drug clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Pharmacy
Biodexa Pharmaceuticals develops drugs to treat rare oncological and neurological diseases. Biotech focused on rare diseases is a volatile niche. The chart below shows the average fluctuations in this sector, allowing you to assess the risks and potential of BDRX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Biodexa Pharmaceuticals is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Biodexa Pharmaceuticals
Biodexa Pharmaceuticals' year-to-date performance tells the story of its diversified development portfolio. Its market cap change over the past 12 months reflects progress in its programs, from treating rare brain diseases to cancer. Its valuation is a bet on at least one of its risky projects reaching the finish line.
Annual dynamics of market capitalization of the market segment - Pharmacy
Biodexa, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biodexa Pharmaceuticals, a company with a diversified portfolio, operates like a "biotech startup fund" in a single stock. Its performance, compared to the market, is an average of successes and failures across multiple verticals, which mitigates the potential for explosive growth from a single drug.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Biodexa Pharmaceuticals
Biodexa is a pharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of the results of its rare disease drug trials are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of rare diseases and oncology. The chart below shows the overall dynamics of the pharmaceutical sector, which serves as the backdrop for evaluating the company's development pipeline.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Its shares move in sync with news about clinical trials and regulatory decisions. The company's performance is uncorrelated with the market and represents a high-risk bet on its scientific developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Biodexa Pharmaceuticals
Shares of Biodexa Pharmaceuticals, a company developing drugs for rare diseases, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials for their drug candidates. The chart below is a clear example of how short-term scientific data and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Pharmacy
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Its shares are buoyed by anticipation of clinical trial results. The chart clearly demonstrates how much the company's performance depends on its own scientific successes and failures, rather than on general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biodexa Pharmaceuticals is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
BDRX - Market capitalization of the company Biodexa Pharmaceuticals
The chart below shows Biodexa Pharmaceuticals' valuation reflecting its new post-merger strategy, focused on treating rare neurological diseases. Its market capitalization now hinges on the success of clinical trials for Huntington's disease treatments. The dynamics illustrate this risky yet socially significant goal.
BDRX - Share of the company's market capitalization Biodexa Pharmaceuticals within the market segment - Pharmacy
Biodexa Pharmaceuticals' market share reflects its focus on developing drugs for rare oncological and neurological diseases. Its market share is based on the potential of its technology for delivering drugs directly to the brain, which could solve one of the major treatment challenges.
Market capitalization of the market segment - Pharmacy
Here's a chart of the total market capitalization of small pharmaceutical companies. Biodexa Pharmaceuticals is an example of such a company with a diversified development portfolio. The graph shows how the market values this high-risk sector, where value is dependent on clinical trial results.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of "second chance" drugs. Biodexa Pharmaceuticals' market capitalization reflects its strategy for repurposing existing drugs to treat rare diseases. The line shows how innovative approaches to R&D compete for market share in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
BDRX - Book value capitalization of the company Biodexa Pharmaceuticals
Biodexa Pharmaceuticals' book value represents its scientific capital. The chart below reflects the valuation of its pipeline of developments and drug delivery technologies targeting rare diseases. The pipeline's growth reflects success in clinical trials, the company's primary asset.
BDRX - Share of the company's book capitalization Biodexa Pharmaceuticals within the market segment - Pharmacy
Biodexa Pharmaceuticals' core competencies are its R&D infrastructure for developing drugs using brain drug delivery technology. The chart shows its share of this specialized scientific infrastructure, which forms the foundation for treating complex CNS diseases.
Market segment balance sheet capitalization - Pharmacy
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Biodexa, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Biodexa Pharmaceuticals is a company specializing in developing drugs for rare diseases and oncology. Its assets are not factories, but a patent portfolio and clinical trial data. The chart shows the material resources devoted to fighting orphan diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Its market capitalization is determined by its pipeline and its brain drug delivery technology.
Market to book capitalization ratio in a market segment - Pharmacy
Biodexa Pharmaceuticals PLC is a pharmaceutical company developing drugs for rare diseases. Its value depends on the success of its clinical programs. This chart shows how its market valuation is essentially an option on future drug approvals and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs to treat rare diseases and cancer. The market valuation shown in this chart is based on the potential of their pipeline. This is a classic example of biotech, where intellectual property is valued far more than tangible assets.
Debts of the company, segment and market as a whole
BDRX - Company debts Biodexa Pharmaceuticals
Biodexa Pharmaceuticals, a clinical-stage company, uses raised capital to develop its drugs for rare diseases. This chart shows how the company spends investor funds on clinical trials, a long, expensive, and risky process with an uncertain outcome.
Market segment debts - Pharmacy
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Its debt load reflects the high costs and risks associated with clinical trials. This chart shows how the company raises capital to fund its research programs and advance niche drugs through the complex regulatory approval process.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Biodexa Pharmaceuticals
Bollinger Innovations, which aims to produce electric trucks, operates in one of the most capital-intensive sectors. Going from prototypes to mass production requires billions. This chart shows how dependent the company is on external funding to realize its ambitious plans in the commercial electric vehicle market.
Market segment debt to market segment book capitalization - Pharmacy
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs to treat rare oncological and neurological diseases. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its clinical-stage research.
Debt to book value of all companies in the market
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Focusing on orphan diseases allows them to avoid direct competition with giants, but it requires specialized expertise. This chart of total market debt helps understand the environment in which the company is raising capital to advance its niche, yet important, developments.
P/E of the company, segment and market as a whole
P/E - Biodexa Pharmaceuticals
For Biodexa Pharmaceuticals, a pharmaceutical company, the P/E ratio is irrelevant. The company doesn't have stable profits. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' faith in the success of clinical trials.
P/E of the market segment - Pharmacy
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs to treat rare oncological and neurological diseases. Its technology enables drug delivery directly to the brain. This chart shows the average valuation for the pharmacy sector, reflecting investor expectations for innovative treatments for diseases of the central nervous system.
P/E of the market as a whole
Biodexa Pharmaceuticals is a British pharmaceutical company developing drugs to treat rare oncological and neurological diseases. The company uses technology to deliver drugs directly to the brain. This risk appetite chart helps understand how investors value early-stage biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for the treatment of rare diseases and oncology. This chart reflects market expectations regarding the success of its clinical trials. Future profits depend entirely on the trial results and commercial potential of its drug candidates.
%20P%2FE%20Biodexa%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Biodexa-Pharmaceuticals&v=1772624315729 "Chart of the company's future (projected) P/E Biodexa Pharmaceuticals")
Future (projected) P/E of the market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company focused on developing drugs for rare diseases and cancer. This chart compares market expectations for its scientific developments. It shows how investors assess the potential of its clinical programs compared to other companies working in similar therapeutic areas.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharmacy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharmacy&v=1772624315821 "Future (projected) P/E graph of the market segment - Pharmacy")
Future (projected) P/E of the market as a whole
Biodexa Pharmaceuticals is a biopharmaceutical company specializing in developing drugs for rare diseases and cancer. Its future depends on successful clinical trials and partnerships. The overall market optimism demonstrated by this chart is important for attracting the investment needed to advance orphan drugs through the complex approval process.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624315904 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Being in the clinical stage, its financial activities are focused on R&D. This chart illustrates the company's financial position, where investments in orphan drug development are key to future commercial success.
Profit of companies in the market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare oncological and neurological diseases. This graph, showing overall sector profitability, highlights the potential of niche markets. Biodexa's success in bringing drugs to market for orphan diseases could generate enormous profits and transform patients' lives.
Overall market profit
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for the treatment of rare diseases and cancer. Its business model is based on advancing candidates through clinical trials. The company's value is determined by scientific data and regulatory decisions, not by overall economic performance.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases and cancer. The future profit projections you see are speculative and depend on the success of clinical trials. Analysts are evaluating the potential of its lead candidates, which target markets with unmet medical needs.
%20profit%20of%20the%20company%20Biodexa%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Biodexa-Pharmaceuticals&v=1772624316016 "Graph of future (projected) profit of the company Biodexa Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharmacy
Biodexa Pharmaceuticals is a specialty pharmaceutical company developing drugs to treat rare oncological and neurological diseases. This chart shows revenue forecasts for the entire pharmaceutical sector. It helps assess how the company's focus on orphan diseases aligns with overall industry trends and patient needs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharmacy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharmacy&v=1772624316031 "Graph of future (predicted) profits of companies in a market segment - Pharmacy")
Future (predicted) profit of the market as a whole
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs to treat rare diseases. Its success is determined by the results of clinical trials. This market sentiment chart is important for Biodexa because it influences investor willingness to finance long-term and risky projects in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624316047 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a biopharmaceutical company specializing in developing drugs to treat rare oncological and neurological diseases. For such a company, this chart is a measure of investor hope. It reflects a valuation based on the potential of its scientific developments, not on current sales revenue.
P/S market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing new treatments for rare diseases and oncology. The company uses its technology platforms to create innovative drugs. This chart reflects investor estimates of biotech revenue, demonstrating expectations for Biodexa's clinical development and scientific potential.
P/S of the market as a whole
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs to treat rare oncological and neurological diseases. Its valuation is based on progress in clinical trials. This chart, showing the average valuation, shows how investors value biotech companies targeting orphan diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases. This chart shows the market's assessment of its potential future revenue from its pipeline of products. It reflects investor confidence in the success of its clinical programs and the commercial potential of its innovative therapies.
%20P%2FS%20Biodexa%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Biodexa-Pharmaceuticals&v=1772624316139 "The graph of the company's future (projected) P/S Biodexa Pharmaceuticals")
Future (projected) P/S of the market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare oncological and neurological diseases. This chart shows the average estimated future revenue in the pharmaceutical sector. It helps understand how investors view the company's clinical development and its chances of bringing new treatments to market for patients with unmet needs.
%20P%2FS%20market%20segment%20graph%20-%20Pharmacy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharmacy&v=1772624316162 "Future (projected) P/S market segment graph - Pharmacy")
Future (projected) P/S of the market as a whole
Biodexa Pharmaceuticals (BDRX) is a pharmaceutical company developing drugs to treat rare diseases. Their future depends on the success of clinical trials and regulatory approval. This general economic outlook chart is not relevant to their business, which is focused on solving highly specialized medical problems.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624316174 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Being in the clinical stage, it does not have stable sales revenue. Its financial history is one of investing in science. The graph reflects future revenue from licensing or sales of its drug candidates after their approval.
Sales of companies in the market segment - Pharmacy
Biodexa Pharmaceuticals (formerly Midatech Pharma) is a pharmaceutical company developing drugs for the treatment of rare diseases. Its current revenue may come from royalties. Future revenue depends on the success of its candidates in oncology and neuroscience, demonstrating its scientific potential.
Overall market sales
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs for rare diseases. Its success is determined by the results of clinical trials. Demand for drugs for orphan diseases is not dependent on economic cycles, but the overall situation shown in this chart affects the availability of capital to fund lengthy and expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a biopharmaceutical company specializing in the development of drugs for the treatment of rare oncological and neurological diseases. Future revenue is dependent on the success of clinical trials. This chart reflects analysts' long-term forecasts for the commercial potential of its developments.
%20sales%20of%20the%20company%20Biodexa%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Biodexa-Pharmaceuticals&v=1772624316244 "Schedule of future (projected) sales of the company Biodexa Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases and cancer. This chart shows the outlook for the pharmaceutical sector. It reflects the overall level of investment and scientific progress in the development of drugs for orphan diseases, which is a strategic focus for Biodexa.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharmacy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharmacy&v=1772624316246 "Schedule of future (projected) sales of companies in the market segment - Pharmacy")
Future (projected) sales of the market as a whole
The pharmaceutical market forecasts, which are part of the overall expectations in this chart, are important for Biodexa Pharmaceuticals. The company develops and commercializes drugs. Its success depends on the stability of the healthcare system and its ability to finance new therapeutic solutions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624316262 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for the treatment of rare oncological and neurological diseases. This chart reflects its current status as a research and development organization. Future profitability is entirely dependent on the success of its lead candidates in clinical trials and regulatory approval.
Market segment marginality - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare oncological and neurological diseases. Profitability depends on the success of its clinical programs. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential of Biodexa's developments in complex and understudied areas of medicine.
Market marginality as a whole
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Its future depends on the success of clinical trials and regulatory approval. This chart reflects the overall investment climate, which determines how easily companies working with orphan diseases can raise capital for their expensive research.
Employees in the company, segment and market as a whole
Number of employees in the company Biodexa Pharmaceuticals
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases. This chart reflects its compact team of scientists and clinicians. A small staff is typical for R&D companies focused on advancing their candidates through complex and expensive clinical trials to market.
Share of the company's employees Biodexa Pharmaceuticals within the market segment - Pharmacy
Biodexa Pharmaceuticals is developing drugs to treat rare diseases and cancer using its drug delivery technologies. This chart shows the company's share of the total number of scientists in its therapeutic areas. This reflects its scientific potential and focus on solving complex medical problems through innovative approaches.
Number of employees in the market segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare oncological and neurological diseases. This chart, reflecting employment in the pharmaceutical industry, provides a general overview. The growing number of scientists specializing in rare diseases indicates increased interest in this field, creating opportunities for Biodexa.
Number of employees in the market as a whole
Biodexa Pharmaceuticals develops and commercializes pharmaceuticals. Like any company in this sector, it depends on investment and the state of the healthcare system. This total employment chart reflects the economic base that allows for the funding of medical innovation and ensures effective demand for new, effective drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals is a biopharmaceutical company focused on rare diseases and cancer. Like other R&D biotech companies, their market value is not based on their headcount. This metric reflects the high value of their "intellectual capital"—their patents and the potential of their drugs in development, particularly for the treatment of brain tumors.
%20of%20the%20company%20Biodexa%20Pharmaceuticals%20(BDRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Biodexa-Pharmaceuticals-BDRX&v=1772624316517 "Chart of market capitalization per employee (in thousands of dollars) of the company Biodexa Pharmaceuticals (BDRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharmacy
Biodexa Pharmaceuticals is a pharmaceutical company focused on developing drugs for rare diseases. Its value depends almost entirely on the success of clinical trials and intellectual property. This metric clearly demonstrates the biotech model, where a small team of scientists can generate market value comparable to that of large companies.
%20by%20market%20segment%20-%20Pharmacy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharmacy&v=1772624316534 "Market capitalization per employee (in thousands of dollars) by market segment - Pharmacy")
Market capitalization per employee (in thousands of dollars) for the overall market
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. Market value in this field depends on the success of clinical trials and the potential of orphan drugs. This chart illustrates how a small, focused team can generate enormous market value by working to solve problems for small patient groups.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624316550 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals (formerly Midatech) is a biotech company developing drugs for rare diseases using its drug delivery technologies. It is an R&D company. This chart shows the company's "burn rate": how much the company spends (negative profit) on each scientist to advance its niche drugs through clinical trials.
%20Chart%20Biodexa%20Pharmaceuticals%20(BDRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Biodexa-Pharmaceuticals-BDRX&v=1772624316559 "Company Profit Per Employee (in thousands of dollars) Chart Biodexa Pharmaceuticals (BDRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharmacy
Biodexa Pharmaceuticals develops drugs using advanced drug delivery technologies. For a research-stage company, this chart reflects project management efficiency. The potential for growth in this indicator is driven by successful clinical trials and partnerships with major pharmaceutical companies to bring drugs to market.
%20in%20the%20market%20segment%20-%20Pharmacy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharmacy&v=1772624316585 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharmacy")
Profit per employee (in thousands of dollars) for the market as a whole
Biodexa Pharmaceuticals (BDRX) is a biopharmaceutical company (formerly Midatech Pharma) developing drugs using proprietary drug delivery technologies. It is an R&D company and has no profit. This metric is negative and reflects the "cost" of one scientist working to improve existing drugs using new technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624316654 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Biodexa Pharmaceuticals (BDRX)
Biodexa Pharmaceuticals is a pharmaceutical company developing drugs for rare diseases. While in clinical trials, it may not have stable revenue. This chart serves as a barometer of the future potential that will be realized upon commercialization of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Biodexa-Pharmaceuticals-BDRX&v=1772624316680 "Sales chart per company employee Biodexa Pharmaceuticals (BDRX)")
Sales per employee in the market segment - Pharmacy
Biodexa (formerly Midatech) is a biotech company focused on drug delivery technologies (for example, for the treatment of brain cancer). This is an R&D company. This graph reflects their clinical stage. Their research team's productivity lies in creating and patenting delivery platforms that can be licensed to major pharma.
Sales per employee for the market as a whole
Cadre Holdings (CDRE) is a manufacturer and distributor of critical equipment for first responders, law enforcement, and the military. Their products include body armor, holsters, and bomb disposal equipment. This chart reflects their performance in the security niche. The company combines in-house production (high margins) with distribution. Success here lies in a strong brand and efficient production.
Short shares by company, segment and market as a whole
Shares shorted by company Biodexa Pharmaceuticals (BDRX)
Biodexa (BDRX), formerly Midatech, is a pharmaceutical company developing drug delivery technologies. This chart shows the number of short positions. The shorts reflect a long history of failures, capital dilution, and skepticism that its technology will ever succeed.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Biodexa-Pharmaceuticals-BDRX&v=1772624316824 "Short Shares Chart for the Company Biodexa Pharmaceuticals (BDRX)")
Shares shorted by market segment - Pharmacy
Biodexa Pharmaceuticals (BDRX) develops drugs for rare diseases and cancer using its drug delivery technologies. The chart below shows a general short position in the biotech sector, demonstrating investor skepticism about the success of risky clinical trials.
Shares shorted by the overall market
Biodexa Pharmaceuticals (formerly Midatech) is a biotech company developing drug delivery platforms. This chart illustrates the overall market pessimism. When fear reigns, investors are reluctant to finance a cash burn. They sell off shares of pre-profitable companies like BDRX, preferring to cash out until the market calms down, without waiting for news on trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Biodexa Pharmaceuticals (BDRX)
This chart for Biodexa (formerly Midatech) is a barometer of faith in drug delivery technology. The company is developing ways to "package" drugs for better penetration into the brain or tumors. "Overheating" (above 70) occurs due to positive preclinical data. Years of setbacks, a change in focus, and a lack of cash lead to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Biodexa-Pharmaceuticals-BDRX&v=1772624316900 "RSI 14 indicator chart for the company's stock Biodexa Pharmaceuticals (BDRX)")
RSI 14 Market Segment - Pharmacy
Biodexa Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases and cancer. Their technology (MTD) aims to create more effective drugs. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
Biodexa Pharmaceuticals (BDRX) focuses on developing drugs for rare diseases. As with most biotechs, access to capital for R&D is a key factor for success. This market "temperature" chart shows when investors are willing to finance such risks. During periods of euphoria (overbought), capital is available. During moments of panic (oversold), investors flee the sector, putting pressure on BDRX.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BDRX (Biodexa Pharmaceuticals)
Biodexa (BDRX) is a biopharmaceutical company developing drugs to treat rare oncological and neurological diseases. This chart shows the average target price. It reflects analysts' speculative assessments of its clinical pipeline and the likelihood of new drug approvals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BDRX-Biodexa-Pharmaceuticals&v=1772624316929 "A chart showing analyst consensus forecasts for the expected stock price. BDRX (Biodexa Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price BDRX (Biodexa Pharmaceuticals)
Biodexa (BDRX) is a biotech company developing drugs (the Tolimidone platform) for the treatment of rare oncologies. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their confidence in this oncology R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BDRX-Biodexa-Pharmaceuticals&v=1772624316943 "A chart showing the difference between the consensus forecast and the actual stock price. BDRX (Biodexa Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharmacy
Biodexa Pharmaceuticals is a biotech company developing drugs to treat rare neurological diseases and cancer. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe R&D investments in this area will be successful.
Analysts' consensus forecast for the overall market share price
Biodexa Pharmaceuticals (BDRX) is a clinical-stage biopharmaceutical company focused on treating rare oncology diseases. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Biodexa Pharmaceuticals
Biodexa Pharma (formerly Midatech) is a biotech R&D company. Their signature technology is a delivery technology (Q-Sphera), which packages existing drugs into microspheres for slow release (e.g., every 6 months). This graph is a pure indicator of their R&D, reflecting their (slow) progress in clinical trials and their ability to form partnerships.
AKIMA Market Segment Index - Pharmacy
Biodexa Pharmaceuticals is a biotech company using unique drug delivery technology (nanoparticles) to treat cancer and rare diseases. They strive to make therapy more precise. This chart compares their composite index to the sector, showing how their technology platform compares to other pharmacies.
The AKIM Index for the overall market
Biodexa Pharmaceuticals is a biopharmaceutical company that acquires and develops products to treat rare diseases and oncology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this asset consolidation strategy compares to overall economic trends.
